Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease
This study has been completed.
Study NCT00035308   Information provided by La Jolla Pharmaceutical Company
First Received: May 2, 2002   Last Updated: September 22, 2006   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Immunologic Diseases
Autoimmune Diseases
Systemic Lupus Erythematosus
Lupus Nephritis
Lupus Glomerulonephritis
Additional conditions recognized in this trial
Glomerulonephritis
Immune System Diseases
Lupus Erythematosus, Systemic
Nephritis
More general conditions related to this trial
Connective Tissue Diseases
Kidney Diseases
Urologic Diseases
Interventions listed in this trial
Abetimus sodium (LJP 394)
Sponsors listed in this trial
La Jolla Pharmaceutical Company


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services